Contextual factors in value-based decision support to enhance health technologies adoption: the case of biosimilars

The workshop underscored the need for value-sensitive implementation strategies that go beyond clinical effectiveness. Integrating context-specific values into evidence-based decision-making can foster trust and support the sustainable adoption of biosimilars. The MCDA framework offers a structured approach to operationalize these principles. Future research should test and refine this model in varied health system settings to support its practical application by policymakers, healthcare providers, and industry stakeholders.

Authors

Institutions

Publication Details

Journal
Frontiers in Pharmacology
Published
2025-08-13
DOI
https://doi.org/10.3389/fphar.2025.1599013
Primary Topic
Biosimilars and Bioanalytical Methods
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Contextual factors in value-based decision support to enhance health technologies adoption: the case of biosimilars

G. Kockaya, Ana Paula Beck da Silva Etges, Deborah M. Mullen, Meindert Boysen et al.
Frontiers in Pharmacology
Biosimilars and Bioanalytical Methods
article

Contextual factors in value-based decision support to enhance health technologies adoption: the case of biosimilars

G. Kockaya, Ana Paula Beck da Silva Etges, Deborah M. Mullen, Meindert Boysen, Ahmed Seyam, Iñaki Gutiérrez‐Ibarluzea, Zoltán Kaló, Hans‐Peter Dauben, Hussain Abdulrahman Al‐Omar, Yingyao Chen, Maximilian Otte
article en

Abstract

The workshop underscored the need for value-sensitive implementation strategies that go beyond clinical effectiveness. Integrating context-specific values into evidence-based decision-making can foster trust and support the sustainable adoption of biosimilars. The MCDA framework offers a structured approach to operationalize these principles. Future research should test and refine this model in varied health system settings to support its practical application by policymakers, healthcare providers, and industry stakeholders.

Frontiers in PharmacologyVol. 16
Semmelweis University (HU), Universidade Federal do Rio Grande do Sul (BR), University of Cologne (DE), Fudan University (CN), Instituto Federal de Educação, Ciência e Tecnologia do Rio Grande do Sul (BR), King Saud University (SA), Education Authority (GB), Procter & Gamble (Belgium) (BE), Estonian Environmental Research Center (Estonia) (EE), ISG Institute for Social Research (DE), Institute of Health Economics (CA), DAK-Gesundheit (Germany) (DE), L.Garde (United States) (US), Syreon Research Institute (Hungary) (HU)
Ewha Womans University, Mahidol University, King Khalid University
Openalex Percentile: Top 78%
Biosimilars and Bioanalytical Methods
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.